{"disease":{"id":"anal-canal-squamous-cell-carcinoma","name":"anal canal squamous cell carcinoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02834013","title":"Nivolumab and Ipilimumab in Treating Patients With Rare Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":818,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03233711","title":"Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":344,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04429542","title":"Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":292,"lead_sponsor_name":"Bicara Therapeutics","has_results":false},{"nct_id":"NCT04166318","title":"Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":252,"lead_sponsor_name":"ECOG-ACRIN Cancer Research Group","has_results":false},{"nct_id":"NCT04444921","title":"EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer Patients","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":205,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05374252","title":"Chemoradiotherapy Combined With or Without PD-1 Blockade in Anal Canal Squamous Carcinoma Patients","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":102,"lead_sponsor_name":"Sixth Affiliated Hospital, Sun Yat-sen University","has_results":false},{"nct_id":"NCT02314169","title":"Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":37,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04221893","title":"Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers","phase":"NA","overall_status":"RECRUITING","enrollment_count":28,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT05060471","title":"PD-1 Blockade Combined With Chemotherapy Followed by Concurrent Immunoradiotherapy for Locally Advanced SCCA Patients","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":25,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT03690921","title":"Linear Energy Transfer (LET)-Optimized Intensity Modulated Proton Therapy (IMPT) as a Component of Definitive Chemoradiation for Newly Diagnosed Squamous Cell Carcinoma of the Anal Canal: a Feasibility Trial","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":8,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT04499352","title":"A Study to Test BI 754091 Alone or in Combination With BI 836880 in People Who Have Advanced Anal Cancer","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Boehringer Ingelheim","has_results":false}],"total":11},"guidelines":[],"source":"Drug Landscape verified database"}